This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrow Correction

 Previous Article  |  Next Article 

AAP News Vol. 26 No. 9 September 2005, p. 11
© 2005 American Academy of Pediatrics

CORRECTION

In the July issue, incorrect information was given in the article titled, "Pimecrolimus shown to be effective anti-inflammatory agent."

Following is the correct information. The Food and Drug Administration (FDA) has released a public health advisory with new safety information concerning pimecrolimus (www.fda.gov/cder/drug/infopage/elidel/default.htm).

The FDA also stated that labeling changes would be required for pimecrolimus, including a black box warning about cancer risk. At this time, however, pimecrolimus does not have a black box warning on its label.





This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrow Correction